- Trials with a EudraCT protocol (416)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
416 result(s) found for: Gastric Cancer.
Displaying page 1 of 21.
EudraCT Number: 2006-001503-10 | Sponsor Protocol Number: 29/2006/O/Sper | Start Date*: 2006-05-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Technology of the radioisotopes for the intra-operative identification of the sentinel node in the premature gastric cancer. Clinical study of feasibility in order to improve the treatment and prog... | |||||||||||||
Medical condition: gastric cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001419-25 | Sponsor Protocol Number: GastricCHIMERAtrial | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Jagiellonian University Medical College | |||||||||||||
Full Title: Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial | |||||||||||||
Medical condition: Gastric Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022699-30 | Sponsor Protocol Number: B-DOCT | Start Date*: 2011-01-19 | |||||||||||||||||||||
Sponsor Name:Nederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis | |||||||||||||||||||||||
Full Title: Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Me... | |||||||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004996-24 | Sponsor Protocol Number: ONCOL1 | Start Date*: 2008-12-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | |||||||||||||
Full Title: A RANDOMIZED PHASE II STUDY OF TAXOTERE, OXALIPLATIN, CAPECITABINE (TOX) OR EPIDOXORUBICIN, OXALIPLATIN AND CAPECITABINE (EOX) IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC C... | |||||||||||||
Medical condition: PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022164-12 | Sponsor Protocol Number: TOG301 | Start Date*: 2012-01-23 | ||||||||||||||||
Sponsor Name:Genta Incorporated | ||||||||||||||||||
Full Title: A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer | ||||||||||||||||||
Medical condition: Histologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prohibited by CA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003301-42 | Sponsor Protocol Number: EMR100070-008 | Start Date*: 2016-05-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Merck KGaA | |||||||||||||||||||||||||||||||||
Full Title: A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma | |||||||||||||||||||||||||||||||||
Medical condition: Unresectable, recurrent, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016468-35 | Sponsor Protocol Number: D8480C00067 | Start Date*: 2016-03-29 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Gastric cancer | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GR (Completed) HU (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002715-40 | Sponsor Protocol Number: CRO-2008-26 | Start Date*: 2008-11-02 | |||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
Full Title: NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY | |||||||||||||
Medical condition: PATIENTS WITH OPERABLE GASTRIC ADENOCARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017151-97 | Sponsor Protocol Number: CRO-2009-58 | Start Date*: 2010-07-01 | |||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
Full Title: PHASE II STUDY OF SECOND LINE TREATMENT WITH WEEKLY NON-PEGILATE LIPOSOMIAL DOXORUBICIN IN METASTATIC GASTRIC CARCINOMA | |||||||||||||
Medical condition: PATIENTS WITH METASTATIC GASTRIC CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004357-86 | Sponsor Protocol Number: GOIRC-05-2019 | Start Date*: 2020-07-17 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (G... | |||||||||||||
Medical condition: HER2 positive advanced gastric or gastro-esophageal junction cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002321-30 | Sponsor Protocol Number: 12.01 | Start Date*: 2012-11-01 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Randomized phase II trial with irinotecan as monotherapy compared to irinotecan and bevacizumab (BevIri) for patietns with platinum resistant non-resectable esophagus-, cardia or gastric cancer | |||||||||||||
Medical condition: Patients with esophagus or gastric cancer and who are platinum resistant and non-resectabel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005046-37 | Sponsor Protocol Number: COUGAR-02 | Start Date*: 2007-12-28 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: COUGAR-02: A randomised phase III study of docetaxel vs active symptom control in patients with relapsed oesophago-gastric adenocarcinoma | ||||||||||||||||||
Medical condition: Advanced oesophago-gastric cancer which has previously been treated with a platinum and fluoropyrimidine based combination | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004512-43 | Sponsor Protocol Number: ML20777 | Start Date*: 2007-01-29 | |||||||||||
Sponsor Name:Roche Farma, S.A. | |||||||||||||
Full Title: Estudio Fase II abierto de Capecitabina (Xeloda®) como fluoropirimidina de elección en combinación con quimioterapia en pacientes con cáncer gástrico Avanzado y/o Metastático susceptibles de ser tr... | |||||||||||||
Medical condition: Capecitabine in combination with chemotherapy in patients with advanced and/or metastatic gastric cancer suitable to be treated with a fluoropirimidine based regimen to assess the safety profile sp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007273-23 | Sponsor Protocol Number: JBZ-CHI-BO-2007-12 | Start Date*: 2008-02-08 | ||||||||||||||||
Sponsor Name:Jeroen Bosch Hospital | ||||||||||||||||||
Full Title: A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer | ||||||||||||||||||
Medical condition: Gastric carcinoma stadium Ib-IVa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003300-23 | Sponsor Protocol Number: EMR100070-007 | Start Date*: 2016-06-13 | |||||||||||||||||||||||||||||||
Sponsor Name:Merck KGaA | |||||||||||||||||||||||||||||||||
Full Title: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metas... | |||||||||||||||||||||||||||||||||
Medical condition: Advanced (unresectable, locally advanced or metastatic) adenocarcinoma of the stomach, or of the gastro-esophageal junction (GEJ) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) RO (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005464-92 | Sponsor Protocol Number: DOCOX-C-00082 | Start Date*: 2006-06-07 | |||||||||||
Sponsor Name:Sanofi-aventis groupe | |||||||||||||
Full Title: Estudio randomizado de fase II de Docetaxel en combinación con Oxaliplatino con o sin 5-FU o Capecitabina, en cáncer gástrico metastásico o en recurrencia local que no haya sido tratado previamente... | |||||||||||||
Medical condition: Cáncer gástrico metastásico o en recurrencia local que no haya sido tratado previamente para la enfermedad avanzada con quimioterapia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) GB (Completed) DE (Completed) HU (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006544-20 | Sponsor Protocol Number: CRAD001R2301 | Start Date*: 2009-07-06 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer af... | |||||||||||||
Medical condition: advanced gastric cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001478-27 | Sponsor Protocol Number: IRFMN-GCC-7813 | Start Date*: 2019-09-11 | |||||||||||
Sponsor Name:Associazione Chirurghi Ospedalieri Italiani | |||||||||||||
Full Title: Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcomes.... | |||||||||||||
Medical condition: Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006088-22 | Sponsor Protocol Number: Gastripec-I | Start Date*: 2011-03-28 | ||||||||||||||||
Sponsor Name:Klinik für Chirurgie, Charité Campus Virchow-Klinikum | ||||||||||||||||||
Full Title: Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carc... | ||||||||||||||||||
Medical condition: Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000853-22 | Sponsor Protocol Number: CA184-162 | Start Date*: 2012-06-13 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally... | ||||||||||||||||||
Medical condition: Locally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
